×
About 89,940 results

Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study
https://link.springer.com/article/10.1007/s10072-020-04519-x

We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 ye...

KESIMPTA® (ofatumumab) - Official Physician Website
https://www.hcp.novartis.com/Efficacy

KESIMPTA® is FDA Approved. Download a Start Form Today. Visit Now to Learn More. Access PI and Start Resources for HCPs. Contact Us for Support. Enrollment Support. Official HCP Website. HCP Resources. FDA Approved. KESIMPTA® Safety Info.

Vitamin D and rheumatoid arthritis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539179/
Therapeutic Advances in Endocrinology and Metabolism; Kostoglou-Athanassiou I

Dec 27th, 2012 - Vitamin D deficiency has been implicated in the pathogenesis of autoimmune diseases, such as diabetes mellitus type 1 and multiple sclerosis. Reduced vitamin D intake has been linked to increased susceptibility to the development of rheumatoid arthritis (RA) and vitamin D deficiency has been found to be associated with disease activity in patients with RA. The objective was to evaluate vitamin ...

PONVORY™ (ponesimod) - For Healthcare Professionals
http://www.ponvoryhcp.com/

Visit the Site to Register and Receive the Info You Need For This Once-Daily Treatment. Coming Soon: The Once-Daily Treatment PONVORY™. Sign Up For More Information! For HCPs. Coming Soon. Sign Up for More Info.

Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162735/
Neurol Sci.; Bonavita S

Apr 16th, 2020 - We propose a possible approach for the remote monitoring of infection risk in people with multiple sclerosis, especially those on immunosuppressant drugs, during COVID-19 pandemic. We developed a digital triage tool to be sent to patients to quickly identify people with high risk of COVID-19 infection. This tool will also limit unnecessary accesses to the MS centers reducing the risk of spreadi...

Effects of Systolic Blood Pressure on Brain Integrity in Multiple Sclerosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026666/
Frontiers in Neurology; Dossi DE

Jun 27th, 2018 - In MS patients, hypertension is associated with a delayed diagnosis and an increased risk of progression. Understanding the mechanisms of this association could potentially lead to improved prevention of disease progression. We aimed to establish whether high blood pressure contributes to white-matter injury and brain atrophy in MS.

NEJM Journal Watch Neurology Top Stories of 2020
https://www.jwatch.org/na52895/2020/12/29/nejm-journal-watch-neurology-top-stories-2020
NEJM Journal Watch; Probasco JC.

On behalf of the editorial board, I am pleased to introduce the NEJM Journal Watch Neurology Top Stories of 2020. In a year dominated by the SARS-CoV-2 global pandemic, there were also practice changing advances for the management of a variety of neurologic diseases. These included potential new treatments for myasthenia gravis, migraine, and spinal muscular atrophy in adults, as well as import...

Prednisone - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK534809/
Puckett Y, Gabbar A et. al.

Prednisone is a synthetic, anti-inflammatory glucocorticoid that derives from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone is an FDA-approved, delayed-release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases including immunosuppressive/endocrine, rheumatic, collagen, dermatologic, allergi...

Immediate and Sustained Effects of Interventions for Changing Physical Activity in People with Multiple Sclerosis: Meta-Analysis of Randomized Controlled Trials
https://www.archives-pmr.org/article/S0003-9993(20)30217-3/pdf
Archives of Physical Medicine & Rehibilitation; Kim Y

Apr 24th, 2020 - To examine the immediate and sustained effects of interventions for changing physical activity behavior in people with multiple sclerosis (MS), and explore factors that might moderate intervention effects on physical activity behavior (e.g., intervention type and duration, type of physical activity measurement, intensity of theory integration [degree of theory used in study design], and study q...

FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
http://media.emdserono.com/2019-03-29-FDA-Approves-MAVENCLAD-R-Cladribine-Tablets-as-First-and-Only-Short-Course-Oral-Treatment-for-Relapsing-Remitting-and-Active-Secondary-Progressive-Multiple-Sclerosis

Mar 28th, 2019 - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved MAVENCLAD® (cladribine) tablets for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS). MAVENCLAD is the first and only FDA-approved treatment for RRMS and ...

Medical Use of Cannabinoids
https://link.springer.com/article/10.1007/s40265-018-0996-1
Drugs Fraguas-Sánchez,A.,et al

Oct 28th, 2018 - Cannabinoid receptors, endocannabinoids and the enzymes responsible for their biosynthesis and degradation constitute the endocannabinoid system. In recent decades, the endocannabinoid system has attracted considerable interest as a potential therapeutic target in numerous pathological conditions. Its involvement in several physiological processes is well known, such as in energy balance, appet...

Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awz099/5481202
Brain Nelson,P.,et al

Apr 29th, 2019 - We describe a recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a stereotypical TDP-43 proteinopathy in older adults, with or without coexisting hippocampal sclerosis pathology. LATE-NC is a common TDP-43 proteinopathy, associated with an amnestic dementia syndrome that mimicked Alzheimer’s-type...

NOVANTRONE® mitoXANTRONE for injection concentrate
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf

NOVANTRONE is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses)

BETASERON® (interferon beta-1b)
https://www.betaseron.com/hcps/

BETASERON® information for healthcare professionals. BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations.

BIOGEN AND ALKERMES ANNOUNCE FDA APPROVAL OF VUMERITY™ (DIROXIMEL FUMARATE) FOR MULTIPLE SCLEROSIS
http://investors.biogen.com/news-releases/news-release-details/biogen-and-alkermes-announce-fda-approval-vumeritytm-diroximel

Nov 5th, 2019 - Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease...

Baclofen
https://www.ncbi.nlm.nih.gov/books/NBK526037/

Dec 15th, 2018 - Baclofen was originally designed in 1960 to treat epilepsy. However, the result was not satisfactory. Baclofen was then reintroduced in 1971 when it was found to treat muscle spasticity and has been widely used since. Baclofen is FDA-approved for the management of reversible spasticity, particularly for the relief of flexor spasms, clonus, and concomitant pain, common sequelae of spinal cord le...

Neurodiem, your daily connection to neuroscience
https://www.neurodiem.com/

Independent, unbiased, and scientifically validated content covering 18 topics including headache, cognition, dementia, pain, epilepsy, movement disorders, neurosurgery, neuro-oncology, multiple sclerosis etc.

AVONEX® (interferon beta-1a)
https://www.avonex.com/en_us/home/additional-support/hcp-resources.html

Find resources about AVONEX (interferon beta-1a) for healthcare professionals, including start forms, insurance information, and formulary access. AVONEX is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS)

Dry Mouth (Xerostomia) Causes: Scleroderma
https://www.biotene.com/what-is-dry-mouth/scleroderma/

70% of individuals diagnosed with Scleroderma (Systemic Sclerosis) show symptoms of Dry Mouth. Learn more about managing Dry Mouth symptom relief.

Landmark Study Estimates Nearly 1 Million in the U.S. Have Multiple Sclerosis
https://www.nationalmssociety.org/About-the-Society/News/Landmark-Study-Estimates-Nearly%C2%A01-Million-in-the-U

Feb 14th, 2019 - A study by leading experts estimates that in 2017, nearly 1 million adults (up to 913,925) were living with MS in the United States. This is more than twice the previously reported number from a national study in 1975 and subsequent updates.